Fig. 3: Antibody responses to the cAd3-Ebola vaccines followed similar dose-dependence and kinetics in the Trial US and Trial UG participants.

Baseline-subtracted antibody titers following cAd3-EBOZ or cAd3-EBO vaccination in the US and UG trial participants as assessed by Ebola Zaire GP ELISA. Data expressed as EC₉₀ titers. In (a, b) titers from weeks 4, 24 and 48 post-cAd3 Ebola vaccination are shown as dot plots overlaid with a line at the geometric mean titer (GMT). Titers were compared between groups from the same country and at the same time using Wilcoxon rank-sum test. Statistical significance is noted as follows: α: significant difference from EBOZ Low, β: Significant difference from EBOZ High, γ: Significant difference from EBO Low, λ: Significant difference from all Low, ζ: Significant difference from all EBOZ, π: significant difference from all Low and EBO High, ω: Significant difference from all non-DNA-primed. The n participants for each comparison and the p values are listed in Supplementary Tables 6 and 7. Results from (a, c) are from a previous clinical trial (NCT02231866), and the results have been partially reported^28,32. Low n participants in (a) at week 48 are due to recruitment of participants into the subsequent Trial US to receive MVA vaccine (NCT02408913). In (c, d), durability of the vaccine-induced antibody titers are expressed as GMTs. Throughout figure, error bars indicate 95% CIs.